1. Home
  2. MUX vs NUVB Comparison

MUX vs NUVB Comparison

Compare MUX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$21.39

Market Cap

1.6B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.52

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUX
NUVB
Founded
1979
2018
Country
Canada
United States
Employees
1432
291
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MUX
NUVB
Price
$21.39
$4.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$26.63
$11.38
AVG Volume (30 Days)
988.1K
4.5M
Earning Date
05-06-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.52
$190.15
Revenue Next Year
$26.24
$62.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.38
$1.57
52 Week High
$29.70
$9.75

Technical Indicators

Market Signals
Indicator
MUX
NUVB
Relative Strength Index (RSI) 47.99 45.66
Support Level $17.91 $4.07
Resistance Level $26.94 $5.55
Average True Range (ATR) 1.23 0.22
MACD 0.03 0.06
Stochastic Oscillator 52.12 77.78

Price Performance

Historical Comparison
MUX
NUVB

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: